Sonova Holding (SWX:SOON) used its EUHA congress media briefing to spotlight Roger On Sphere and the Integro CI processor family, pushing further into AI-powered hearing hardware and smarter cochlear implant ecosystems.
Recent pricing points to gathering momentum in Sonova Holding, with the share price at CHF283.2 and a 30 day share price return of 17.0% feeding into a 36.0% year to date gain. The 1 year total shareholder return of 26.3% and 3 year total shareholder return of 43.1% sit against a 5 year total shareholder return that has declined 18.0%.
Scan beyond Sonova Holding and compare it with hand-picked peers shaping AI-driven hearing and health tech progress through the 124 healthcare AI stocks.
Sonova Holding now has AI-heavy products and a fast rising share price. The business looks strong. The real test is whether that recent surge already reflects the value on offer.
Most Popular Narrative: 13% Overvalued
On the most followed view, Sonova Holding carries a fair value of CHF250.37, which sits below the last close at CHF283.20. This means the current price reflects a premium to that narrative.
The current valuation implies Sonova Holding is already priced for the company to deliver its guided 5% to 10% constant-currency sales CAGR and 7% to 12% core EBIT CAGR over the midterm without major upside or downside being assumed.
See why 27 investors see Sonova Holding as 13% overvalued.
Result: Fair Value of CHF250.37 (OVERVALUED)
Still, the Sonova Holding story can change quickly if FX headwinds persist or if European cochlear implant pricing pressure continues to weigh on that segment.
Find out about the key risks to this Sonova Holding narrative.
Another View: Sonova Holding Through The Earnings Multiple Lens
Analyst narratives lean toward Sonova Holding trading above fair value, yet the earnings multiple picture looks more mixed. The current P/E of 31.3x is almost identical to its fair ratio of 31.4x, suggesting the market may already be close to the level that regression analysis points to.
Set that against peers and the signal shifts. Sonova Holding trades above the wider European medical equipment group at 28x P/E, which implies less margin for error if earnings disappoint. However, it sits well below a 51.8x peer average, which points to less aggressive pricing than some rivals. The question is whether you view that gap as a buffer against downside, or a sign that the market is already cautious for good reason.
See what the numbers say about this price, find out in our valuation breakdown See what the numbers say about this price — find out in our valuation breakdown.
Next Steps
Sentiment around Sonova Holding is split, and that tension is exactly why you should inspect the data yourself and decide quickly where you stand. To see what investors view as the main upside drivers, take a closer look at the 2 key rewards.
Looking for more investment ideas beyond Sonova Holding?
Sonova Holding gives you one angle on the hearing and health tech theme. Do not stop there when fresh opportunities could be sitting just a few clicks away.
- Target potential mispriced opportunities by scanning a curated set of quality companies that screen as attractively valued with the Simply Wall Street tool 192 high quality undervalued stocks.
- Strengthen your income stream by focusing on companies that pair higher yields with resilience using the dedicated list of opportunities in the 226 dividend fortresses.
- Dial down portfolio stress by concentrating on financially robust businesses through the Simply Wall Street list of solid balance sheet and fundamentals (204 results).
Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com